4-(Tri-n-butylstannyl)pyridine → (R)-3'-[4-(4-Pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one
Reaktionsgleichung
Br[C:2]1[CH:3]=[C:4]([N:7]2[CH2:11][C@:10]3([CH:16]4[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]4)[CH2:12]3)[O:9][C:8]2=[O:19])[O:5][CH:6]=1.C([Sn](CCCC)(CCCC)[C:25]1[CH:30]=[CH:29][N:28]=[CH:27][CH:26]=1)CCC>>[N:28]1[CH:29]=[CH:30][C:25]([C:2]2[CH:3]=[C:4]([N:7]3[CH2:11][C@:10]4([CH:16]5[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]5)[CH2:12]4)[O:9][C:8]3=[O:19])[O:5][CH:6]=2)=[CH:26][CH:27]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared by a method analogous to that described in Example 14 from (R)-3′-(4-bromofuran-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one and 4-(tri-n-butylstannyl)pyridine. The title compound (21 mg) was obtained as a pale solid, m/z (MH+).
Aufarbeitung
- customThe title compound was prepared by a method analogous to